Who Paid My Doc
Eric Suhler
Uveitis and Ocular Inflammatory Disease Portland, OR Medical Doctor
NPI 1275585143 CMS profile 329701
3375 Sw Terwilliger Blvd, Bldg 10N112, Portland, OR 97239
General payments
$36,745
Research payments
$15,532
Ownership & investment interest
$0
Research they led as principal investigator
$310,099
Through program year 2025, Eric Suhler of Portland, OR is reported in the CMS Open Payments database as having received $36,745 across 34 general payments and $15,532 in research payments paid to them. Separately, studies naming them as principal investigator received $310,099 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $8,841 | 7 | |
| 2025 | Research | $2,019 | 2 | |
| 2024 | General | $14,725 | 12 | |
| 2024 | Research | $8,602 | 10 | |
| 2023 | General | $7,729 | 7 | |
| 2023 | Research | $4,851 | 8 | |
| 2022 | General | $5,143 | 3 | |
| 2020 | General | $121 | 1 | |
| 2019 | General | $188 | 4 | |
| 2019 | Research | $61 | 1 |
Beside peers
- Eric Suhler
- Uveitis and Ocular Inflammatory Disease median
- Middle half of Uveitis and Ocular Inflammatory Disease
- National median
In program year 2025, general payments to Eric Suhler were reported at $8,841. Among 42 Uveitis and Ocular Inflammatory Disease profiles paid that year, the median was $471 and the middle half received between $198 and $5,376.
Show as a table
| Year | Eric Suhler | Uveitis and Ocular Inflammatory Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $188 | $403 | $156–$5,734 | $163 |
| 2020 | $121 | $164 | $99–$6,393 | $114 |
| 2021 | $0 | $240 | $102–$2,572 | $132 |
| 2022 | $5,143 | $503 | $154–$5,143 | $149 |
| 2023 | $7,729 | $655 | $222–$5,436 | $160 |
| 2024 | $14,725 | $567 | $227–$2,571 | $164 |
| 2025 | $8,841 | $471 | $198–$5,376 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
101
Drug cost
$118,052
Branded share of claims
21.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Humira(Cf) Pen Adalimumab | Brand | 11 | $113,169 | |
| Difluprednate | Generic | 12 | $2,384 | |
| Prednisolone Acetate | Generic | 31 | $1,242 | |
| Mycophenolate Mofetil | Generic | 16 | $763 | |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | Brand | 11 | $315 | |
| Prednisone | Generic | 20 | $179 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 15 billing codesPaid by Medicare
$20,340
Medicare patients
90
Services billed
487
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 57% | |
| Arthritis | 42% | |
| Diabetes | 24% | |
| Depression | 23% | |
| Cancer | 19% | |
| Osteoporosis | 19% | |
| Chronic kidney disease | 17% | |
| Ischemic heart disease | 16% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
55 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Uveitis and Ocular Inflammatory Disease in Oregon
Related records
Uveitis and Ocular Inflammatory Disease in Oregon
Practitioners in the same specialty and state, ranked by reported value.
All Uveitis and Ocular Inflammatory Disease
Everyone recorded under this specialty, nationwide.
Doctors in Oregon
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.